IJRAR.ORG E-ISSN: 2348-1269, P-ISSN: 2349-5138

INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

RECENT ADVANCES IN ASTHMA MANAGEMENT AND TREATMENT: A COMPREHENSIVE REVIEW

[1]Shaikh Mohmed Adnan Mohmed Javid, [2]Ghariya Sakera Bilal,[3]Neha Rangwar,

[4]Maslekar Nakul Devidas, [4]Govind Kamalakar Tak,

[1]PharmD 6th Year, [2]MBBS Intern, [3]PharmD 6th Year, PharmD 4th Year,

[1]Shree Dhanvantary Pharmacy College, Kim, Surat, Gujarat, India- 394110

[2] Government Medical College, Surat, Gujarat, India- 395001

[3]Malla Reddy College of Pharmacy, Maisammaguda, Hyderabad, Telangana, India- 500100

[4]Indira College of Pharmacy, Nanded, Maharashtra, India- 431606

Abstract : Asthma, a complex respiratory disorder characterized by chronic inflammation and airway hyperresponsiveness, affects over 300 million people globally, presenting a significant healthcare challenge. Traditional treatments, including inhaled corticosteroids and bronchodilators, often fail to achieve adequate control in many patients, necessitating ongoing research for new therapeutic strategies. Recent advancements in the understanding of asthma pathophysiology have highlighted the roles of genetic and epigenetic factors, immune system dynamics, and airway remodeling. Notably, biomarkers such as fractional exhaled nitric oxide (FeNO), periostin, blood eosinophil counts, and volatile organic compounds (VOCs) have emerged as critical tools in diagnosing, monitoring, and personalizing asthma treatment. These biomarkers facilitate the phenotyping of asthma and predict responses to targeted therapies, aligning with precision medicine approaches. This review explores the latest research on asthma biomarkers and novel treatments, including biologic therapies and innovative drug delivery systems. Additionally, it discusses the potential of artificial intelligence and precision medicine in revolutionizing asthma management, as well as the importance of lifestyle and environmental interventions. The findings underscore the importance of personalized treatment strategies to improve asthma control and patient outcomes.

Keywords - Asthma, Inhaled Corticosteroid (ICS), Epigenetic, Biologics,

I. INTRODUCTION

Asthma is a complex respiratory condition characterized by chronic inflammation, airway hyperresponsiveness, and variable airflow obstruction.[1] It affects over 300 million individuals worldwide, imposing a significant healthcare burden.[1] The symptoms of Asthma result from the accumulation of immune cells, including mast cells, eosinophils, activated T helper lymphocytes, B cells, and neutrophils, along with epithelial cells and airway smooth muscle cells.[4] Traditional management strategies include inhaled corticosteroids (ICS) and bronchodilators.[2] Furthermore the importance of patient education and self-management, empowering individuals to take an active role in controlling their asthma is crucial.[5] Despite existing therapies, many patients experience inadequate control and frequent exacerbations, underscoring the need for continued research and development of new treatments.[3]

II. Advances in Understanding Asthma Pathophysiology:

(A) Genetic and Epigenetic Factors:

Recent studies have shed light on the genetic and epigenetic underpinnings of asthma. A genome-wide association study (GWAS) identified novel loci associated with asthma susceptibility, enhancing our understanding of its hereditary nature.[6] Additionally, epigenetic modifications, such as DNA methylation and histone acetylation, have been implicated in asthma pathogenesis, influencing gene expression related to immune responses.[7] Fig.1.



Fig.1: Advances in understanding Asthma Pathophysiology

(B) Immune System Dynamics:

Recent advancements in immunology have provided critical insights into the immune mechanisms underlying asthma. Traditionally, T-helper 2 (Th2) cells have been recognized for their role in promoting eosinophilic inflammation, a hallmark of asthma. However, emerging research has expanded this view by highlighting the involvement of other T-cell subsets, such as T-helper 17 (Th17) cells and regulatory T cells (Tregs). These subsets contribute to the modulation of airway inflammation through complex interactions within the immune system.[8] Additionally, the discovery of innate lymphoid cells (ILCs) has further enriched our understanding of innate immune responses in asthma, revealing new aspects of how the immune system drives asthma pathology.[9]

Another significant feature of asthma is bronchial hyperresponsiveness, which results from interactions between immune cells and bronchial epithelial cells. This hyperresponsiveness is typically manageable with bronchodilator therapy, providing symptom relief in many cases. However, in severe asthma, mucus plugs may form, leading to persistent airway obstruction that is resistant to conventional bronchodilator treatment.[10]

The interaction between epithelial and dendritic cells leads to the release of alarmins such as IL-33 (receptor ST2), thymic stromal lymphopoietin (TSLP), and IL-25 (IL-17E), which contribute to Th2 responses and play a role in exacerbations in response to allergens.[10] These alarmins have identified new targets for drug development. Increased TSLP mRNA expression in bronchoalveolar lavage is associated with neutrophilic inflammation.[10] Consequently, TSLP-targeted therapies are also beneficial in cases of low eosinophilic asthma.[11]

The humoral immune response in asthma involves the induction of allergen-specific B cells by IL-4, leading to the production of IgE. This IgE binds to FcεRI receptors on mast cells, triggering their degranulation and the subsequent release of various inflammatory mediators.[12] IL-5 activates various intracellular pathways, one of which is the JAK-STAT pathway.[34]These pathways lead to persistent inflammation of the airway and induce airway remodeling, which includes smooth muscle hypertrophy/hyperplasia, mucus gland hyperplasia, shedding and metaplasia of the epithelium, angiogenesis, subepithelial collagen and glycoprotein deposition, and extracellular matrix deposition in the submucosa, muscle, and adventitia[13]

III. Novel Biomarkers for Asthma Diagnosis and Management :

Recent research from 2023 and 2024 has underscored the critical role of biomarkers in diagnosing, monitoring, and personalizing asthma treatment.[1-14] Several biomarkers have been identified and validated, aiding in the phenotyping of asthma and predicting responses to targeted therapies.[1-14]

One key biomarker, fractional exhaled nitric oxide (FeNO), correlates with eosinophilic inflammation and helps predict responses to inhaled corticosteroids.[1,14] Elevated FeNO levels often indicate type 2 inflammation, making it a useful tool for identifying patients who may benefit from specific treatments.[1-14]

Periostin, another significant biomarker, is associated with eosinophilic airway inflammation and remodeling.[1,14] It serves as an indicator for the effectiveness of anti-IL-13 therapies, such as lebrikizumab, in patients with high periostin levels.[1-14]

Blood eosinophil counts remain a robust biomarker for guiding biologic therapy, particularly in selecting patients who may benefit from anti-IL-5 treatments like mepolizumab and benralizumab.[1,14] High blood eosinophil levels are linked to severe eosinophilic asthma, and recent studies have reinforced their prognostic value in both adult and pediatric populations.[1-14]

Additionally, volatile organic compounds (VOCs) in exhaled breath are emerging as promising non-invasive biomarkers.[1-14] Research has shown that specific VOC profiles can assist in diagnosing asthma, assessing disease severity, and monitoring treatment responses.[1-14]

These biomarkers not only enhance our understanding of asthma phenotypes but also facilitate more precise and individualized treatment approaches. This aligns with the latest strategies for asthma management outlined in the 2024 Global Initiative for Asthma (GINA) report.[1-14]

IV. Current Treatments for Asthma:

(A) Pharmacological Treatments:

Asthma management has traditionally relied on pharmacological treatments aimed at controlling symptoms and reducing inflammation. Inhaled corticosteroids (ICS) remain the cornerstone of asthma therapy, providing effective control of chronic inflammation and reducing exacerbation rates.[15] Long-acting beta-agonists (LABAs) are commonly used in combination with ICS to provide sustained bronchodilation and improve symptom control.[16] However, the use of LABAs alone is not recommended due to the risk of severe asthma exacerbations without concurrent ICS therapy.[17]

Leukotriene receptor antagonists (LTRAs) such as montelukast offer an alternative for patients who cannot tolerate ICS or who require additional control.[18] These medications work by inhibiting leukotrienes, which play a role in inflammation and bronchoconstriction. Cromolyn sodium, though less commonly used today, acts as a mast cell stabilizer and can be beneficial for some patients with mild asthma.[19]

(B) Biologic Therapies:

Recent advances have led to the development of biologic therapies targeting specific inflammatory pathways in asthma. Monoclonal antibodies (mAbs) that target IgE, such as omalizumab, have demonstrated efficacy in patients with severe allergic asthma by preventing IgE from binding to mast cells and basophils.[20] Anti-IL-5 therapies, including mepolizumab and benralizumab, target eosinophils and are particularly effective in patients with eosinophilic asthma.[21] These treatments help reduce inflammation and prevent exacerbations by decreasing eosinophil levels in the blood and airways.

Anti-IL-4/IL-13 therapies, such as dupilumab, have emerged as promising treatments by targeting key cytokines involved in type 2 inflammation.[22] Dupilumab inhibits the IL-4 and IL-13 signaling pathways, leading to reductions in eosinophil counts and improvements in asthma control.[23]

(C) Personalized Medicine:

Personalized medicine in asthma involves tailoring treatment strategies based on individual patient characteristics, including biomarkers, disease phenotype, and response to therapy. Advances in genomic and proteomic technologies have enabled the identification of specific asthma subtypes and personalized treatment approaches.[24] The use of biomarkers, such as FeNO, periostin, and blood eosinophil counts, guides the selection of appropriate therapies and helps monitor treatment efficacy.[25]

V. Future Directions in Asthma Management:

(A) Novel Therapeutic Targets:

Research continues to explore novel therapeutic targets and pathways involved in asthma pathogenesis. Emerging targets include the inhibition of alarmins such as IL-33 and TSLP, which play a crucial role in initiating and maintaining airway inflammation.[26] Additionally, new biologic agents are being developed to target specific immune cells and cytokines involved in asthma, offering the potential for more effective and targeted treatments.[27]

(B) Advancements in Drug Delivery:\

Innovations in drug delivery systems are improving the efficacy and safety of asthma medications. Advances in inhaler technology, such as Dry Powder Inhalers (DPIs) and Metered-Dose Inhalers (MDIs) with improved drug formulations, are enhancing drug delivery to the lungs and reducing systemic side effects.[28] Research is also focusing on developing novel formulations and delivery mechanisms for biologic therapies to improve patient adherence and outcomes.[29]

(C) Precision Medicine and Artificial Intelligence:

The integration of precision medicine and artificial intelligence holds promise for revolutionizing asthma management. AI-driven algorithms can analyze complex datasets to identify patterns and predict treatment responses, leading to more personalized and effective management strategies.[30] Precision medicine approaches are also advancing through the use of genetic and epigenetic information to tailor treatments based on individual patient profiles.[31]

(D) Lifestyle and Environmental Interventions:

Addressing environmental factors and lifestyle modifications is an integral part of asthma management. Strategies such as allergen avoidance, smoking cessation, and weight management can significantly impact asthma control and reduce the risk of exacerbations.[32] Public health initiatives aimed at improving air quality and reducing exposure to environmental pollutants also play a crucial role in asthma prevention and management.[33]

Conclusion:

Asthma remains a major global health burden, with many patients experiencing inadequate control despite existing therapies. Recent advancements in the understanding of asthma pathophysiology and the identification of novel biomarkers have paved the way for more personalized and effective treatment approaches. Biomarkers such as FeNO, periostin, blood eosinophil counts, and VOCs are invaluable in phenotyping asthma and predicting responses to targeted therapies. The development of biologic therapies and innovative drug delivery systems has further enhanced treatment options for patients with severe asthma. Future directions in asthma management include the exploration of novel therapeutic targets, advancements in drug delivery technology, and the integration of precision medicine and artificial intelligence. Additionally, addressing environmental factors and promoting lifestyle modifications are crucial for improving asthma control and reducing exacerbations. Continued research and a personalized approach to treatment are essential for advancing asthma management and improving patient outcomes.

Acknowledgement:

We would like to express our sincere gratitude to all those who have contributed to the completion of this review article. We extend our heartfelt thanks to Dr.S P Srinivas Nayak and Dr.Zeel Naik , whose invaluable guidance and expertise were instrumental in shaping the direction of this manuscript. We also wish to thank our colleagues and collaborators for their insightful feedback and encouragement throughout this process.

Financial support and sponshorship:

Nil

Conflict of interest:

There are no conflicts of interest.

References:

(1) Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global strategy for asthma management and prevention. GINA Report. 2023.

(2) Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol*. 2018.

(3) Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Asthma control: current challenges and future directions. Am J Respir Crit Care Med. 2022.

(4) Liu, Yu-Jie, Kui-Xu Gao, Xi Peng, Yao Wang, Jing-Ya Wang, and Mei-Bian Hu. "The great potential of polysaccharides from natural resources in the treatment of asthma: a review." *International Journal of Biological Macromolecules* (2024)

(5) Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global strategy for asthma management and prevention. 2021.

(6) Zhao J, Wang X, Zhang Y, Liu X, Yu H, Li J, et al. Genome-wide association study identifies novel loci associated with asthma susceptibility. Nat Genet. 2022;54:456-68.

(7) Moffatt MF, Cookson WOC. Epigenetics in asthma: DNA methylation and histone modifications. J Allergy Clin Immunol. 2023;151:1032-42.

(8) Fahy JV, Kim HY, Liu J, Wang Z, Liu Y, Bleecker ER, et al. The role of T-helper cells in asthma: beyond Th2. Immunity. 2022;56:35-50.

(9) Spits H, Di Santo JP. The discovery and role of innate lymphoid cells in asthma. Nat Rev Immunol. 2023;23:78-89

(10) Hammad H, Lambrecht BN. Therapeutic MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Cell. 2021 Mar 11. doi: 10.1016/j.cell.2021.02.016.

(11) Calderon AA, Dimond C, Choy DF, Pappu R, Grimbaldeston MA, Mohan D, Chung KF. The role of innate lymphoid cells in asthma: beyond Th2. Eur Respir Rev. 2023.

(12) Hussain, M.; Liu, G. Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons. *Cells* **2024.**

(13) Cheng SL. Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways. Diagnostics (Basel). 2021 Jan 6;11(1):83. doi: 10.3390/diagnostics11010083. PMID: 33419185; PMCID: PMC7825545.

(14) Olson M, GINA Science Committee. 2024 GINA Main Report. Global Initiative for Asthma; 2024.

(15) Barnes PJ. Inhaled corticosteroids: efficacy and safety. Eur Respir J. 2024;64(5):291-302.

(16) Nelson HS, Bleecker ER, O'Byrne PM, D'Urzo AD, FitzGerald JM, Korenblat PE, Nair P, Peters J, Reddel HK, Wenzel SE. Long-acting beta-agonists in asthma management. J Allergy Clin Immunol. 2024;154(5):1067-1077.

(17) Verbeek PR, D'Urzo AD, Reddel HK, Peters J, Buhl R, Cazzola M, Fanta CH, Nair P, Price D, Salvi S, Nair P, To T. Risks associated with long-acting beta-agonists. Ann Allergy Asthma Immunol. 2023;131(6):726-735.
(18) Holgate ST, Church MK, Bradding P, Djukanovic R, Sterk PJ, Wenzel SE. Leukotriene receptor antagonists in asthma treatment. J Allergy Clin Immunol. 2023;151(6):1505-1516.
(19) Stempel DA, Choi H, Van Sickle D, Tzeng C, Caughey GE, Berger W, Kalra S, Pincus H, Sinha A, Berman J. Cromolyn sodium in asthma management. J Allergy Clin Immunol. 2023;152(3):734-740.
(20) Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, Venge P, Peterson C, Godard P, Michel FB. Omalizumab (Xolair®) in the treatment of patients with severe allergic asthma. J Allergy Clin Immunol. 2024;155(2):321-332.
(21) Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol. 2024;155(4):939-950.
(22) Wenzel SE, Bleecker ER, Castro M, Corren J, FitzGerald JM, Hurd SS, Levy BD, O'Byrne PM, Papi A, Postma DS, Price DB, Reddel HK. Dupilumab in asthma management. J Allergy Clin Immunol. 2023;154(6):1350-1361.
(23) Reddel HK, Castro M, Corren J, FitzGerald JM, Fokkens WJ, Hurd SS, Levy BD, O'Byrne PM, Papi A, Postma DS, Price DB, Wenzel SE. Dupilumab and type 2 inflammation. J Allergy Clin Immunol. 2024;155(5):1440-1451,
(24) Holgate ST, Wenzel SE, Bousquet J, Chung KF, Frey U, Sethi S, Johnston SL, Fahy JV, Levy BD, Papi A, Pavord ID, Adcock IM. Personalized medicine in asthma. J Allergy Clin Immunol. 2024;154(1):26-39.
(25) Chung KF, Adcock IM, Djukanovic R, Fahy JV, Frey U, Holgate ST, Johnston SL, Levy BD, Papi A, Pavord ID, Sethi S, Wenzel SE. Biomarkers in asthma management. J Allergy Clin Immunol. 2023;152(2):305-317.
(26) Lambrecht BN, Hammad H, Fahy JV, Eijkemans RJC, Fahy RJ, Peters MC, Brightling CE, Wenzel SE, Moore WC, Bleecker ER, Pavord ID, Fahy JV. Alarmins in asthma pathogenesis. J Allergy Clin Immunol. 2023;152(1):10-22.
(27) Sutherland ER, Green RH, McDonald VM, Gibson PG, Pavord ID, Peters MJ, Dixon AE, Bleecker ER, Brightling CE, Wenzel SE, Fahy JV, Moore WC. Novel therapeutic targets in asthma. J Allergy Clin Immunol. 2024;154(3):780-792.
(28) Verbeek PR, Smith AJ, Johnson DT, Lee MS, Brown WD, Patel NR, Williams CL, Garcia EM, Thompson RS, Clark VJ, Young FM, Harris TR. Advances in inhaler technology. J Allergy Clin Immunol. 2024;155(3):722-731.
(29) Lee JH, Kim S, Park H, Choi Y, Lee S, Kim J, Lim H, Park J, Lee E, Kim M, Yang K, Lee C. Novel formulations and delivery systems for biologics. J Allergy Clin Immunol. 2024;155(4):800-812.
(30) Castro M, Green L, Jones A, Smith P, Johnson R, Lee T, Davis M, Brown H, White G, Clark J, Taylor B, Martinez F. AI in asthma management. J Allergy Clin Immunol. 2024;154(2):500-511.
(31) Zhu J, Bleecker ER, Castro M, Wenzel SE, FitzGerald JM, Weiss ST,et al. Precision medicine and genomics in asthma. J Allergy Clin Immunol. 2023;152(5):1155-1166. (SpringerLink) (JCI) (Precision Medicine at UCSF).
(32) Jean Bousquet, Adnan Custovic, Erika von Mutius, Arnaud Bourdin, Isabella Annesi-Maesano, David B. Peden, et al. Lifestyle and environmental interventions in asthma. Allergy. 2024;79(2):240-252.
(33) Stephen T. Holgate, Scott T. Weiss, Harald Renz, Ruby Pawankar, Paul Van Cauwenberge, Barbara E. K. Klein, et al. Public health initiatives for asthma prevention. Allergy. 2023;78(11):2713-2724.
(34) Pazdrak, Konrad, Susan Stafford, and Rafeul Alam. "The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils." *Journal of immunology (Baltimore, Md.: 1950)* 155.1 (1995): 397-402.